Endometrial Carcinoma
Conditions
Keywords
endometrial, carcinoma, recurrent, metastatic, Trisenox, arsenic trioxide, Phase II, VEGF, gynecology, Lineberger, UNC, vascular endothelial growth factor, University of North Carolina at Chapel Hill
Brief summary
The primary purpose of this study is to see whether women who have already received chemotherapy for their endometrial cancer, or who have disease that has spread outside of the uterus, will respond to the drug arsenic trioxide (Trisenox®) as judged by shrinkage of their tumor.
Detailed description
This is an open-label, single arm, single institution, phase II trial designed to assess the response rate and safety of Trisenox® in women with recurrent endometrial carcinoma. Trisenox® will be administered at a dose of 0.25 mg/kg/day for 5 consecutive days (D1-5) every 4 weeks. A 4-week period will be defined as a cycle of treatment. Marker and non-marker lesions will be assessed every 2 cycles (every 8 weeks) and the response assigned according to Gynecologic Oncology Group (GOG) RECIST guidelines. Safety will be assessed by routine physical, laboratory and ECG evaluations. Up to 10 patients will be enrolled into the study. Patients are expected (excluding any unforeseen toxicities) to receive a minimum of 2 and a maximum of 6 cycles of Trisenox®. (Patients with at least documented stable disease may be eligible for \>6 cycles). Patients will be followed for 6 months after their last dose of Trisenox®. For this trial we would allow one prior cytotoxic regimen since the time of recurrence and patients may have had one prior regimen as part of their induction chemotherapy. Patients will be treated with 0.25 mg/kg/day for days 1-5 every 28 days and patients may remain on trial until progression of disease.
Interventions
DRUGArsenic trioxide
Arsenic trioxide - 0.25 mg/kg/day for 5 consecutive days, every 4 weeks.
Sponsors
Cephalon
UNC Lineberger Comprehensive Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. ≥18 years of age with histologically confirmed metastatic or recurrent endometrial cancer 2. Documented progression of their endometrial cancer (i.e., within the last 3 months) 3. If of childbearing potential they must agree to use approved barrier methods of contraception 4. Presence of at least one measurable lesion that: * Can be accurately measured in at least one dimension with longest diameter ≥20 mm using conventional techniques or ≥10 mm with spiral CT scan (or otherwise at least twice the reconstruction interval for CT or MRI scans). * Previously irradiated lesions may be considered to be measurable provided: 1) there has been documented progression of the lesion(s) since completion of radiotherapy, and 2) the criteria for measurability as outlined above are met. 5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 6. Minimum life expectancy of 3 months 7. Adequate renal and hepatic function (per study protocol guidelines) 8. Adequate bone marrow function (per study protocol guidelines) 9. Serum cholesterol \<350 mg/dL and triglycerides \< 400 mg/dL 10. Able to understand and give written informed consent 11. Ejection fraction \>55% with no focal left ventricular wall motion abnormalities in patients with a history of coronary artery disease or a history of congestive heart failure.
Exclusion criteria
1. Women who are pregnant or lactating 2. Presence of brain metastases 3. Two or more prior cycles of cytotoxic chemotherapy since recurrence (Two total regimens are allowed if one includes adjuvant therapy.) 4. Prior therapy with Trisenox or known sensitivity to this agent 5. Prior anticancer treatment (chemotherapy, radiotherapy, immunotherapy, biological response modifiers, signal transduction inhibitors, etc) within 4 weeks prior to the first dose of Trisenox. 6. Ongoing toxicity associated with prior anticancer therapy (except peripheral neuropathy of ≤ grade 1 by NCI toxicity criteria) 7. Another primary malignancy within the past three years (except for non-melanoma skin cancer and cervical carcinoma in situ) 8. Significant uncontrolled cardiovascular disease 9. Active infection requiring systemic therapy 10. Known HIV infection 11. Treatment with any investigational agent within 4 weeks prior to the first dose of Trisenox 12. Concurrent treatment with immunosuppressive agents other than prescribed corticosteroids 13. Inadequate recovery from any prior surgical procedure or having undergone any major surgical procedure within 2 weeks prior to the first dose of Trisenox 14. Patients having undergone recent placement of a central venous access port will be considered eligible if they have recovered 15. Presence of any other life-threatening illness or organ system dysfunction which, in the opinion of the Investigator, would either compromise the patient's safety or interfere with evaluating the safety of the study drug 16. Prolonged absolute corrected QT interval (QTc) interval \> 500 msec 17. Underlying conduction disease that prevents measurement of QT interval 18. History of ventricular tachycardia or any cardiac arrhythmia requiring the placement of an automated intraventricular cardiac defibrillator. 19. Inability to discontinue therapy with class I or class III antiarrhythmic medications. 20. Inability to discontinue drugs known to be associated with a risk for torsades de pointes
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response (CR+PR) Rate of Subjects Given Trisenox | 28 days | To estimate the objective response (CR+PR) rate (as defined by the Gynecologic Oncology Group \[GOG\] RECIST Criteria)of Trisenox® in women with recurrent or metastatic endometrial cancer when administered at 0.25 mg/kg/day for 5 consecutive days (D1-5) every 4 weeks. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival in Patients Treated With Trisenox® | 28 days | Progression-Free survival is the period from start of treatment until disease progression, death, or date of last contact. |
| Overall Survival | 5 years | — |
| Associations Between Markers of Angiogenesis (e.g. VEGF) With Response | 4 years | We will request a blood sample to measure vascular endothelial growth factor (VEGF) as well as other angiogenic factors and correlate levels to response to arsenic trioxide. Such effects have been observed in cultured cell lines and animal models, as well as clinical studies. |
Countries
United States
Participant flow
Recruitment details
Women 18 years of age with histologically confirmed metastatic or recurrent endometrial cancer at the Lineberger Comprehensive Cancer Center
Participants by arm
| Arm | Count |
|---|---|
| Trisenox Treatment Arsenic trioxide: Arsenic trioxide - 0.25 mg/kg/day for 5 consecutive days, every 4 weeks. | 3 |
| Total | 3 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | progression while on treatment | 3 |
Baseline characteristics
| Characteristic | Trisenox Treatment |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 1 Participants |
| Age, Categorical Between 18 and 65 years | 2 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 3 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 2 Participants |
| Region of Enrollment United States | 3 participants |
| Sex: Female, Male Female | 3 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 2 / 3 |
| other Total, other adverse events | 3 / 3 |
| serious Total, serious adverse events | 2 / 3 |
Outcome results
Primary
Objective Response (CR+PR) Rate of Subjects Given Trisenox
To estimate the objective response (CR+PR) rate (as defined by the Gynecologic Oncology Group \[GOG\] RECIST Criteria)of Trisenox® in women with recurrent or metastatic endometrial cancer when administered at 0.25 mg/kg/day for 5 consecutive days (D1-5) every 4 weeks.
Time frame: 28 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Trisenox Treatment | Objective Response (CR+PR) Rate of Subjects Given Trisenox | 0 Participants |
Secondary
Associations Between Markers of Angiogenesis (e.g. VEGF) With Response
We will request a blood sample to measure vascular endothelial growth factor (VEGF) as well as other angiogenic factors and correlate levels to response to arsenic trioxide. Such effects have been observed in cultured cell lines and animal models, as well as clinical studies.
Time frame: 4 years
Population: No patients achieved a CR or PR response, no angiogenesis was performed.
Secondary
Overall Survival
Time frame: 5 years
Population: All patients who received treatment
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Trisenox Treatment | Overall Survival | 320 days |
Secondary
Progression Free Survival in Patients Treated With Trisenox®
Progression-Free survival is the period from start of treatment until disease progression, death, or date of last contact.
Time frame: 28 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Trisenox Treatment | Progression Free Survival in Patients Treated With Trisenox® | 0 Participants |